🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07595107
Starting soon Observational

Concordance Between Large Language Model and Multidisciplinary Team Recommendations in Rectal Cancer

NCT07595107 · tracked via the Priya Life Science China tracker
Sponsor
Shandong Cancer Hospital and Institute
Phase
Observational
Started
2026-06-01
Last updated
2026-05-19

Condition(s) studied

Rectal Cancer

Investigational drug(s) / intervention(s)

Large Language Model Recommendation Generation

Large Language Model Recommendation Generation: For each enrolled case, a standardized de-identified clinical summary will be entered into a locally deployed large language model using a fixed prompt and fixed inference parameters. The model will generate a structured treatment recommendation for concordance assessment. The large language model output will not be disclosed to the multidisciplinary team and will not influence actual patient management.

Study summary

This prospective single-center observational study will evaluate the concordance between recommendations generated by a locally deployed large language model and standardized multidisciplinary team recommendations for patients with rectal cancer.

Consecutive adult patients with pathologically confirmed rectal adenocarcinoma who are scheduled for routine rectal cancer multidisciplinary team discussion will be enrolled. For each case, investigators will prepare a standardized de-identified clinical summary before the multidisciplinary team meeting. The same summary will be used for large language model generation and routine multidisciplinary team discussion.

The large language model recommendation will not be disclosed to the clinical team and will not influence actual patient management. Concordance between the large language model recommendation and the multidisciplinary team reference recommendation will be assessed using predefined structured rules and blinded expert review.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Age 18 years or older. 2. Pathologically confirmed rectal adenocarcinoma. 3. Scheduled for routine rectal cancer multidisciplinary team discussion at the study center. 4. Availability of complete or substantially complete standardized decision-making information before multidisciplinary team discussion, including clinical, pathological, and key imaging information. 5. Availability of a structured pelvic magnetic resonance imaging report meeting the requirements of the institutional rectal cancer multidisciplinary team, including at least tumor location, clinical T stage, clinical N stage, circumferential resection margin or mesorectal fascia status, extramural vascular invasion status, and lateral lymph node status. 6. Presence of a defined clinical treatment decision question. 7. Clinical data can be sufficiently de-identified for research use. Exclusion Criteria: 1. Severely incomplete clinical information preventing preparation of a standardized case summary. 2. Non-rectal primary tumor. 3. Routine follow-up cases without a defined treatment decision question. 4. Absence of a structured pelvic magnetic resonance imaging report meeting the requirements of the institutional rectal cancer multidisciplinary team, or missing pelvic magnetic resonance imaging elements that preclude key rectal cancer decision-making. 5. Cases containing sensitive information considered unsuitable for large language model input by the study team. 6. Cases in which a definitive treatment decision has already been made before the multidisciplinary team discussion and the meeting serves only as a formal review.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Department of Radiation Oncology, Shandong Cancer Hospital and Institute Jinan Shandong

More Shandong Cancer Hospital and Institute trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07595107 on ClinicalTrials.gov ↗ ← All trials in China